Free Trial

Sarepta Therapeutics (SRPT) Stock Price, News & Analysis

Sarepta Therapeutics logo
$109.90 -0.96 (-0.87%)
(As of 12:15 PM ET)

About Sarepta Therapeutics Stock (NASDAQ:SRPT)

Key Stats

Today's Range
$109.03
$110.87
50-Day Range
$104.54
$132.02
52-Week Range
$78.67
$173.25
Volume
301,364 shs
Average Volume
1.23 million shs
Market Capitalization
$10.50 billion
P/E Ratio
87.92
Dividend Yield
N/A
Price Target
$181.33
Consensus Rating
Buy

Company Overview

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Sarepta Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
98th Percentile Overall Score

SRPT MarketRank™: 

Sarepta Therapeutics scored higher than 98% of companies evaluated by MarketBeat, and ranked 26th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sarepta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 20 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Sarepta Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Sarepta Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Sarepta Therapeutics are expected to grow by 438.65% in the coming year, from $2.07 to $11.15 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sarepta Therapeutics is 88.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.26.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sarepta Therapeutics is 88.69, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 87.86.

  • Price to Book Value per Share Ratio

    Sarepta Therapeutics has a P/B Ratio of 8.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Sarepta Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    5.86% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently decreased by 1.06%, indicating that investor sentiment is improving.
  • Dividend Yield

    Sarepta Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Sarepta Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.86% of the outstanding shares of Sarepta Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Sarepta Therapeutics has a short interest ratio ("days to cover") of 6.6.
  • Change versus previous month

    Short interest in Sarepta Therapeutics has recently decreased by 1.06%, indicating that investor sentiment is improving.
  • News Sentiment

    Sarepta Therapeutics has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Sarepta Therapeutics this week, compared to 10 articles on an average week.
  • Search Interest

    42 people have searched for SRPT on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 9 people have added Sarepta Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sarepta Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $822,100.00 in company stock.

  • Percentage Held by Insiders

    Only 7.70% of the stock of Sarepta Therapeutics is held by insiders.

  • Percentage Held by Institutions

    86.68% of the stock of Sarepta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Sarepta Therapeutics' insider trading history.
Receive SRPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SRPT Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…
Sarepta recent weakness brings buying opportunity, says JPMorgan
See More Headlines

SRPT Stock Analysis - Frequently Asked Questions

Sarepta Therapeutics' stock was trading at $96.43 at the beginning of 2024. Since then, SRPT shares have increased by 15.0% and is now trading at $110.86.
View the best growth stocks for 2024 here
.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) posted its quarterly earnings data on Wednesday, August, 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. The company's revenue was up 38.9% on a year-over-year basis.

Sarepta Therapeutics subsidiaries include these companies: Myonexus Therapeutics, Eisai, Sarepta Securities Corp., Sarepta Therapeutics Three LLC, and ST International Holdings Two Inc..

Sarepta Therapeutics' top institutional investors include Janus Henderson Group PLC (4.56%), Wellington Management Group LLP (2.85%), Geode Capital Management LLC (1.78%) and Jacobs Levy Equity Management Inc. (0.79%). Insiders that own company stock include Douglas S Ingram, Michael Andrew Chambers, Richard Barry, Ian Michael Estepan, Hans Lennart Rudolf Wigzell, Bilal Arif, Dallan Murray, Ryan Edward Brown, Kathryn Jean Boor, Stephen Mayo and Louise Rodino-Klapac.
View institutional ownership trends
.

Shares of SRPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sarepta Therapeutics investors own include Zomedica (ZOM), NVIDIA (NVDA), Humana (HUM), American Water Works (AWK), Meta Platforms (META), Voyager Therapeutics (VYGR) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/07/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/26/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRPT
Previous Symbol
NASDAQ:AVII
Employees
1,314
Year Founded
1980

Price Target and Rating

Average Stock Price Target
$181.33
High Stock Price Target
$230.00
Low Stock Price Target
$109.00
Potential Upside/Downside
+63.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
22 Analysts

Profitability

Net Income
$-535,980,000.00
Pretax Margin
7.89%

Debt

Sales & Book Value

Annual Sales
$1.64 billion
Book Value
$9.19 per share

Miscellaneous

Free Float
88,165,000
Market Cap
$10.59 billion
Optionable
Optionable
Beta
0.81

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:SRPT) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners